Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ProQR Therapeutics (PRQR) Net Margin (2021 - 2025)

ProQR Therapeutics' Net Margin history spans 5 years, with the latest figure at 167.32% for Q4 2025.

  • On a quarterly basis, Net Margin rose 4638.0% to 167.32% in Q4 2025 year-over-year; TTM through Dec 2025 was 265.77%, a 11723.0% decrease, with the full-year FY2025 number at 265.21%, down 11835.0% from a year prior.
  • Net Margin hit 167.32% in Q4 2025 for ProQR Therapeutics, up from 382.69% in the prior quarter.
  • Over the last five years, Net Margin for PRQR hit a ceiling of 42.7% in Q2 2024 and a floor of 7623.85% in Q4 2021.
  • Historically, Net Margin has averaged 1460.0% across 5 years, with a median of 441.24% in 2023.
  • The widest YoY moves for Net Margin: up 577704bps in 2022, down -113905bps in 2022.
  • Tracing PRQR's Net Margin over 5 years: stood at 7623.85% in 2021, then surged by 76bps to 1846.81% in 2022, then soared by 92bps to 150.3% in 2023, then tumbled by -42bps to 213.7% in 2024, then increased by 22bps to 167.32% in 2025.
  • Business Quant data shows Net Margin for PRQR at 167.32% in Q4 2025, 382.69% in Q3 2025, and 336.94% in Q2 2025.